| abstract |
The present invention relates to an isolated specific binding molecule which binds human Anx-A1and comprises the complementarity-determining regions (CDRs) VLCDR1, VLCDR2, VLCDR3, VHCDR1, VHCDR2 and VHCDR3, wherein each of said CDRs has an amino acid sequence as follows: VLCDR1 has the sequence set forth in SEQ ID NO: 1, 36 or 37; VLCDR2 has the sequence set forth in SEQ ID NO: 2; VLCDR3 has the sequence set forth in SEQ ID NO: 3; VHCDR1 has the sequence set forth in SEQ ID NO: 4; VHCDR2 has the sequence set forth in SEQ ID NO: 5; and VHCDR3 has the sequence set forth in SEQ ID NO: 6; or, for each sequence, an amino acid sequence with at least 85% sequence identity thereto. The specific binding molecule disclosed is therapeutically useful and in particular may be used in therapy for T-cell mediated diseases, including autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus,obsessive compulsive disorder (OCD),and OCD-related diseases, such as anxiety disorders. |